Although there have been no clinical trials to conclusively establish a cause-and-effect relationship between ovulation induction with clomiphene citrate or gonadotropins and cancer, evidence derived from prospective and cohort studies suggests the following:
Although there have been no clinical trials to conclusively establish a cause-and-effect relationship between ovulation induction with clomiphene citrate or gonadotropins and cancer, evidence derived from prospective and cohort studies suggests the following:
Ovarian cancer: No correlation between fertility drugs and ovarian cancer exists, but nulligravid women and those with borderline ovarian tumors or certain tumor histologies may be at increased risk.
Breast cancer: Studies to date have had conflicting results, showing both increases as well as decreases in risk. Given that breast cancer is widely held to have a hormonal etiology, further studies examining a possible association between the disease and ovulation-inducing agents are needed.
Brinton LA, Moghissi KS, Scoccia B, et al. Ovulation induction and cancer risk. Fertil Steril. 2005;83:261-274.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More